Custom Search


Thursday 01 March 2001

[Clinical study of topotecan in the treatment of small cell lung cancer and recurrent ovarian cancer]

By: Feng F, He X, Shi Y.

Zhonghua Zhong Liu Za Zhi 2001 Mar;23(2):155-8

OBJECTIVE: To evaluate the effect and adverse reaction of China made topotecan in the treatment of small-cell lung cancer (ACLC) and recurrent ovarian cancer (OV). METHODS: From January to July, 2000, topotecan was used to treat 141 patients at a dose of 1.2 mg/m2, given daily as 30-min i.v. infusion for 5 days. Treatment was repeated once every 3 weeks. Of the 141 patients, 118 were evaluable for therapeutic efficacy. All the patients received a total of 286 cycles of treatment were assessable for analysis of adverse reactions. RESULTS: Among the evaluable patients, there were 5 CR, 35 PR, with an overall response rate (RR) of 33.8%. There were 3 CR and 26 PR in 89 patients with SCLC (RR 32.5%). The response rate of patients with or without prior chemotherapy was 15.6% and 50%, respectively. In 29 patients with recurrent OV, there were 2 CR and 9 PR (RR 37.9%). The major toxic effect was myelosuppression. Non-hematopoietic toxicities were mild and tolerable. CONCLUSION: Topotecan is an effective drug for the treatment of SCLC and recurrent OV. It is still efficacious in some patients who previously received standard chemotherapy. The major dose-limiting toxicity is myelosuppression. The response rate and toxicity of the domestically made topotecan are comparable with those of the imported one.

Use of this site is subject to the following terms of use